IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED

PHASE4RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2025

Conditions
Laceration of SkinAnxietyDischarge Time
Interventions
DRUG

Intranasal Midazolam

Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.

DRUG

Intranasal Dexmedetomidine

See above

DRUG

Intranasal Ketamine

See above

Trial Locations (1)

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER